Roche has reported mid-stage results that put its lead obesity candidate closer to the front of a fast-moving race dominated by Eli Lilly and Novo Nordisk. The Swiss group said its once-weekly injectable Roche CT-388 obesity drug achieved up to 22.5% placebo-adjusted weight loss at 48 weeks in a phase 2 trial among participants who adhered to the treatment regimen.…